Last reviewed 2026-04-22 · How we verify

Antidiabetic background therapy

Antidiabetic background therapy refers to baseline glucose-lowering medications used as a control or comparator arm in diabetes clinical trials.

Antidiabetic background therapy refers to baseline glucose-lowering medications used as a control or comparator arm in diabetes clinical trials. Used for Type 2 diabetes mellitus (as background/comparator therapy in clinical trials).

At a glance

Mechanism of action

This is not a single drug entity, but rather a categorical descriptor for standard-of-care antidiabetic agents (such as metformin, sulfonylureas, DPP-4 inhibitors, or insulin) used as background treatment in phase 3 trials. It serves as the therapeutic foundation against which investigational agents are evaluated for additional efficacy and safety.

Approved indications

• Type 2 diabetes mellitus (as background/comparator therapy in clinical trials)

Common side effects

No common side effects on file.

Key clinical trials

• Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3
• Effect of Henagliflozin on Myocardial Fibrosis in Non-Obstructive HCM: A Randomized, Double-Blind, Placebo-Controlled Trial Using 68Ga/18F-FAPI PET/CMR (NA)
• Phase III Trial of SGLT2 Inhibitor and Thiazolidinedione Fixed-Dose Combination vs. Monotherapy in Type 2 Diabetes Patients on Metformin (PHASE3)
• To Assess the Risk of Acute Pancreatitis in Patients With Type 2 Diabetes Mellitus Treated With Empagliflozin
• Effects of empagliFlozin on myocardIal metabOlic Rate of glucosE Estimated Through 18FDG PET (FIORE Study) (PHASE4)
• Phase 3 Alogliptin Pediatric Study (PHASE3)
• Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy
• Head-to-head Comparison of Empagliflozin and Dapagliflozin

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.